The impact of levodopa on post-stroke depression: the ESTREL-depression-study

Area of Science:

• Neuroscience
• Clinical Neurology
• Psychiatry

Background:

• Post-stroke depression (PSD) is a common complication affecting stroke patient recovery.
• Dopamine plays a role in mood and motivation, and low levels are associated with PSD.
• Investigating treatments for PSD is crucial for improving patient outcomes.

Purpose of the Study:

• To determine if levodopa treatment influences the incidence of post-stroke depression (PSD).
• To assess the efficacy of levodopa in managing emotional well-being during stroke rehabilitation.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled trial (ESTREL-Depression) was conducted.
• Participants received either levodopa/carbidopa or placebo for 39 days during in-hospital rehabilitation.
• PSD was assessed at 3 months using the Patient-Reported Outcomes Measurement Information System (PROMIS) short-form depression-4a.

Main Results:

• The study included 407 participants (209 levodopa, 198 placebo).
• At 3 months, the frequency of PSD was 26% in the levodopa group and 28% in the placebo group.
• Levodopa treatment showed no significant effect on the odds of developing PSD (OR = 0.93).

Conclusions:

• Levodopa treatment did not demonstrate a significant impact on the occurrence of post-stroke depression.
• Further research may be needed to explore alternative therapeutic strategies for PSD.